Great Lakes Retirement Inc. Has $847,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Great Lakes Retirement Inc. grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 1.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,859 shares of the medical equipment provider’s stock after acquiring an additional 186 shares during the period. Great Lakes Retirement Inc.’s holdings in Hologic were worth $847,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Venturi Wealth Management LLC bought a new position in shares of Hologic in the 3rd quarter valued at approximately $29,000. NBC Securities Inc. acquired a new position in Hologic in the 3rd quarter valued at $33,000. Bartlett & CO. Wealth Management LLC bought a new position in Hologic in the 4th quarter worth $33,000. Deseret Mutual Benefit Administrators lifted its position in Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 155 shares during the last quarter. Finally, Salem Investment Counselors Inc. boosted its holdings in Hologic by 163.9% during the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 341 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders have sold a total of 32,846 shares of company stock worth $2,473,443 in the last three months. Insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HOLX. StockNews.com lowered Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Raymond James upped their price target on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. UBS Group raised their price objective on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Finally, Needham & Company LLC raised their price target on shares of Hologic from $83.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Hologic has a consensus rating of “Hold” and an average price target of $86.89.

Hologic Price Performance

HOLX traded up $0.68 during midday trading on Thursday, reaching $78.03. 1,068,693 shares of the company’s stock were exchanged, compared to its average volume of 1,841,611. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The business has a 50-day simple moving average of $74.73 and a two-hundred day simple moving average of $71.84. The firm has a market capitalization of $18.32 billion, a price-to-earnings ratio of 36.71, a price-to-earnings-growth ratio of 2.58 and a beta of 1.00. Hologic, Inc. has a one year low of $64.02 and a one year high of $87.88.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.07 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.02 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.